



Contact: Linda A. Tempelman, PhD, VP for Research

Location: Newton, MA

Email: ltempelman@ginerinc.com

Tel: 781 529 0514

Website: www.ginerinc.com

## Company Overview

**Industry Sector:** Medical Devices

### Company Overview:

- 2013 spinout from Giner Inc, the world-leading electrochemistry company with a 40-year history of innovation and excellence
- Specialist in on-demand generation of oxygen for medical applications with optimal purity and moisture content
- Beachhead application is islet implantation for diabetics: preserving pancreata and islet implants with oxygen will make this a mainstream treatment – effective even for type I diabetes in young people

**Target Market:** Transplant hospitals worldwide

## Key Value Drivers

**Technology\*:** *P3S Persufflator* provides conditioned oxygen to the pancreas vasculature preserving islets and islet function better between donor and recipient or islet isolation. *Implantable Oxygenator* is a miniature device supplying oxygen to subcutaneous islet capsules

**Competitive Advantage:** The combination of these 2 technologies results in a highly cost effective complete treatment for type 1 and 2 diabetes giving recipients full insulin regulation ability with no or only local immunosuppression

**Plan & Strategy:** seeking funding to accelerate progress

\*P3S technology funded by the NIDDK and being commercialized under the NIH-CAP SBIR grant; implantable technology funded by Juvenile Diabetes Research Foundation (JDRF)

## Management

### Leadership:

Andy Belt, CEO

Linda Tempelman: PhD, VP for Research

Nic Chronos, MD: Chief Medical Officer

Simon Stone: Chief Design Engineer

### World Wide Scientific Advisory Board:

Klearchos Papas, PhD: Director of the Institute for Cellular Transplantation, University of Arizona

Tom Loudovaris, PhD: Saint Vincent's Institute, Melbourne, Australia; co-founder of TheracYTE

## Product Pipeline

	Phase 0	Phase 1	Phase 2	Phase 3	Launch
<b>P3S Persufflator for Pancreas Organ Preservation</b>					
			expect to complete Phase 2 activities within 3 months expect to begin clinical trial in Edmonton within 3 months		
<b>Implantable Oxygenator for Islet Capsules</b>					
			initial JDRF funding/support		